Active Ingredient History
Rabeprazole sodium was discovered by Eisai Co., Ltd. Janssen Pharmaceutica N.V. and Eisai Co., Ltd. have a strategic alliance in which Eisai and Janssen-Cilag co-promote the drug in Germany and the U.K. In the US rabeprazole sodium is co-promoted under the brand name AcipHex by Eisai Inc. and Janssen Pharmaceutica Inc. Pariet is available through Janssen-Cilag in most other countries excluding Japan and some Asian countries. Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. Rabeprazole is a prodrug and is converted to the active sulphenamide form in the acid environment of the parietal cells. Rabeprazole is used to heal and maintain the healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), for healing Duodenal Ulcers, and for treatment of pathological hypersecretory conditions such as Zollinger-Ellison Syndrome. Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell and does not exhibit anticholinergic or histamine H2-receptor antagonist properties. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor which blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfonamide. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Duodenal Ulcer (approved 1999)
Gastroesophageal Reflux (approved 1999)
Zollinger-Ellison Syndrome (approved 1999)
Adenocarcinoma (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 1)
Arthritis, Rheumatoid (Phase 3)
Asthma (Phase 3)
Atrial Fibrillation (Phase 4)
Autoimmune Diseases (Phase 1)
Bacterial Infections (Phase 4)
Biological Availability (Phase 1)
Bismuth (Phase 4)
Cholangiocarcinoma (Phase 1)
Communicable Diseases (Phase 1)
Deglutition Disorders (Phase 2)
Drug Interactions (Phase 1)
Duodenal Ulcer (Phase 2/Phase 3)
Dyspepsia (Phase 4)
Endoscopy (Phase 3)
Esophageal Diseases (Phase 3)
Esophageal Motility Disorders (Phase 2)
Esophagitis (Phase 2)
Esophagitis, Peptic (Phase 4)
Exocrine Pancreatic Insufficiency (Phase 1)
Fibrosis (Phase 1)
Food-Drug Interactions (Phase 1)
Gastritis (Phase 4)
Gastrointestinal Diseases (Phase 4)
Healthy Volunteers (Phase 4)
Heartburn (Phase 4)
Heart Diseases (Phase 3)
Helicobacter Infections (Phase 4)
Helicobacter pylori (Phase 4)
Intestinal Neoplasms (Phase 4)
Laryngopharyngeal Reflux (Phase 4)
Leukemia, B-Cell (Phase 1)
Liver Cirrhosis (Phase 2/Phase 3)
Marijuana Use (Phase 1)
Nasal Obstruction (Phase 2)
Neoplasms (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 1)
Osteoarthritis (Phase 3)
Peptic Ulcer (Phase 4)
Peptic Ulcer Hemorrhage (Phase 4)
Pharmacokinetics (Phase 1)
Pharyngeal Diseases (Phase 4)
Respiratory Aspiration (Phase 4)
Stomach Diseases (Phase 3)
Stomach Neoplasms (Phase 4)
Stomach Ulcer (Phase 2/Phase 3)
Tuberculosis (Phase 4)
Venous Thromboembolism (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
